The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Branch retinal vein occlusion (BRVO) is when a blockage forms in the veins branching off the retina, which can disrupt blood flow. Treatment depends on the type of blockage and severity of the damage.
CRVO occurs when blood can no longer travel through the main blood vessel that brings blood to the back of the eye. This can cause swelling, and it may lead to vision loss. The retina is a layer of ...
– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion. This is the third ...
DelveInsight’s “Retinal Vein Occlusion Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It ...
Anti-VEGF Therapy and Beyond: The Future of Retinal Disease Treatment Anti-VEGF therapy is a significant breakthrough in the treatment of retinal disease; however, Dr. David Brown stresses the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback